Literature DB >> 16087899

Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.

J Martí-Fàbregas1, M Borrell, D Cocho, R Belvís, M Castellanos, J Montaner, J Pagonabarraga, A Aleu, L Molina-Porcel, J Díaz-Manera, Y Bravo, J Alvarez-Sabín, A Dávalos, J Fontcuberta, J-L Martí-Vilalta.   

Abstract

OBJECTIVE: To determine whether pretreatment markers of coagulation and fibrinolysis are related to recanalization and functional outcome.
METHODS: The authors included patients treated with IV rt-PA with occlusion on baseline transcranial Doppler (Thrombolysis in Brain Ischemia [TIBI] criteria) in whom recanalization within 6 hours was monitored. At baseline, the authors recorded data about demographics, vascular risk factors, the NIH Stroke Scale (NIHSS) score, early CT signs, etiology, blood glucose, and time to rt-PA. The authors also measured plasmatic markers of coagulation (fibrinogen, prothrombin fragments 1 + 2, Factor XIII, Factor VII) and fibrinolysis (alpha2-antiplasmin, Plasminogen Activator Inhibitor, Functional Thrombin Activatable Fibrinolysis Inhibitor [fTAFI]). A favorable outcome was defined as a modified Rankin score < 2 at 3 months.
RESULTS: The authors studied 63 patients with a mean age of 67.3 +/- 12.5 years. The median NIHSS score was 16. Patients who recanalized had lower concentrations of alpha2-antiplasmin (87.5 +/- 18% vs 96.5 +/- 12.5%, p = 0.023) and fTAFI (91.7 +/- 26.7% vs 104.4 +/- 21%, p = 0.039). A multivariant logistic regression analysis showed that the level of alpha2-antiplasmin was the only predictive variable of recanalization (OR 0.95, 95% CI 0.91, 0.99, p = 0.038), while the NIHSS score was the only predictive variable of functional outcome (OR 0.81, 95% CI 0.72, 0.92, p = 0.001).
CONCLUSION: Baseline levels of alpha2-antiplasmin were predictive of recanalization but were not related to the long-term outcome in patients treated with rt-PA within the first 3 hours.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087899     DOI: 10.1212/01.wnl.0000171704.50395.ba

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Blood biomarkers of ischemic stroke.

Authors:  Glen C Jickling; Frank R Sharp
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

2.  Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin.

Authors:  Guy L Reed; Aiilyan K Houng; Dong Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-25       Impact factor: 8.311

Review 3.  α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.

Authors:  Guy L Reed; Aiilyan K Houng; Satish Singh; Dong Wang
Journal:  Semin Thromb Hemost       Date:  2016-07-29       Impact factor: 4.180

4.  Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke.

Authors:  Satish Singh; Aiilyan K Houng; Guy L Reed
Journal:  Neuroscience       Date:  2017-12-30       Impact factor: 3.590

5.  Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke.

Authors:  Mark M McDonald; Jeremy Wetzel; Stuart Fraser; Andrea Elliott; Ritvij Bowry; Jorge F Kawano-Castillo; Chunyan Cai; Navdeep Sangha; Jessica Messier; Amanda Hassler; Joancy Archeval-Lao; Stephanie A Parker; Mohammad H Rahbar; Evan G Pivalizza; Tiffany R Chang; James C Grotta
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

6.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

Review 7.  Blood Biomarkers for Stroke Diagnosis and Management.

Authors:  Joseph Kamtchum-Tatuene; Glen C Jickling
Journal:  Neuromolecular Med       Date:  2019-03-04       Impact factor: 3.843

8.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

Review 9.  Biomarkers for stroke.

Authors:  Suk Jae Kim; Gyeong Joon Moon; Oh Young Bang
Journal:  J Stroke       Date:  2013-01-31       Impact factor: 6.967

10.  Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.

Authors:  Edina Gabriella Székely; Katalin Réka Czuriga-Kovács; Zsuzsanna Bereczky; Éva Katona; Zoltán András Mezei; Attila Nagy; Noémi Klára Tóth; Ervin Berényi; László Muszbek; László Csiba; Zsuzsa Bagoly
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.